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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody tests of varying specificity and
sensitivity are now available. For informing individuals whether they have had coronavirus disease 2019
(COVID-19), they need to be very accurate. For measuring population prevalence of past infection, the
numbers of false positives and negatives need to be roughly equal.
With a series of worked examples for a notional population of 100,000 people, we show that even test
systems with a high specificity can yield a large number of false positive results, especially where the
population prevalence is low. For example, at a true population prevalence of 5%, using a test with 99%
sensitivity and specificity, 16% of positive results will be false and thus 950 people will be incorrectly
informed they have had the infection. Further confirmatory testing may be needed.
Giving false reassurance on which personal or societal decisions might be based could be harmful for
individuals, undermine public confidence and foster further outbreaks.
© 2020 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.To help reverse the current lockdowns while suppressing
COVID-19 rates, we need to identify who currently has the infection
and who has had it and recovered. As reverse transcriptase poly-
merase chain reaction (RT-PCR) testing to detect current infection
has been recently discussed in detail,1 we focus in this article on
antibody tests. The presence or absence of antibodies can inform
individuals if they have had the infection or not and guide personal
and societal decisions about if and when they can return to normal
activities. Antibody testing thus needs to be particularly accurate. It
can also be used to provide an estimate of the population preva-
lence of previous infection. We demonstrate that for this purposeof Edinburgh, Edinburgh, EH8
leben), raj.bhopal@ed.ac.uk
health@gmail.com (L. Gruer),
(J. Stebbing), florian.stigler@
h. Published by Elsevier Ltd. All rihigh accuracy is not required, but the numbers of false positives and
false negatives need to be approximately equal.
Antibody tests are increasingly available but with variable ac-
curacy. It is hoped they can be used to identify people who are at
least partially immune. Immunity certificates, a more appropriate
phrase than immunity passports that promises too much, for in-
dividuals thought to have recovered from COVID-19, are being
discussed internationally.2e4 Whether tests are carried out for
clinical diagnosis, screening or immunity certificates, we need to
have sufficient confidence they are accurate.
A sensitive test will detect the presence of antibodies to SARS-
CoV-2 (the virus that causes COVID-19), and a specific test will
not react to other antibodies e.g. to other coronaviruses. No diag-
nostic or screening test is perfect and incorrect results are inevi-
table, not least because the timing of the test is critical.
Seroconversion takes time, with IgM, IgG and IgA antibodies usu-
ally developing in that order, and can be variable and dependent
upon the severity of the illness and the individual's immuneghts reserved.
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test systems may perform less well than the manufacturers' results
suggest. For example, both Roche and Abbott reported their anti-
body test had 100% sensitivity for samples taken 14 days or more
after the onset of symptoms, yet Public Health England found
sensitivity at 14 or more days of only 87% and 93.4%, respectively.5,6
We show here how to measure the test's accuracy and how this
changes along with the prevalence of disease (12 tables showing
the results with varying sensitivity, specificity and population
prevalence of 1%, 5%, 10% and 20% are available in the Supple-
mentary File). The two key measures of its accuracy are sensitivity
and specificity, set out in Table 1, with the cells identified as A (true
positives), B (false positives), C (false negatives) and D (true nega-
tives). Sensitivity (A/A þ C) is the proportion of people with a dis-
ease who, when tested, receive a positive test result. It is also
known as the true positive rate. Specificity (D/D þ B) is the pro-
portion of individuals without a disease who, when tested, receive
a negative test result. It is also known as the true negative rate.
To establish sensitivity and specificity, we could test a sample
of patients with proven disease (in this case laboratory detection
of SARS-CoV-2), and a sample of people known to be free of dis-
ease (for example, using stored blood samples taken before
COVID-19 existed in humans). In practice, a test's performance will
usually be poorer than the values established due, for example, to
problems in storing or transporting specimens or the variable time
lag from the onset of infection until antibodies appear in the blood
(seroconversion) and then decline. The proportion of test results
that are false partly depends on the prevalence of the disease in
the population. With a low prevalence, even a test with high
sensitivity and specificity will produce a high proportion of false
positives. In this article, we focus on the outcomes of tests of
variable accuracy with 5% population prevalence in a hypothetical
group of 100,000 people, of whom 5000 have had the infection
and 95,000 have not. This is a plausible current prevalence of past
COVID-19 in many countries7e9 although it could be a lot higher in
some areas.Table 1
Predictive powers of a test with 90% sensitivity and specificity (5% prevalence).
Test result (90% sensitivity and 90% specificity) People truly with d
Positive 4500 (A)
Negative 500 (C)
Total 5000
Predictive value of a positive test: A/A þ B ¼ 32.1%.
Predictive value of a negative test: D/D þ C ¼ 99.4%.
Table 2
Predictive powers of a test with 80% sensitivity and 99% specificity (5% prevalence).
Test result (80% sensitivity and 99% specificity) People truly with d
Positive 4000 (A)
Negative 1000 (C)
Total 5000
Predictive value of a positive test: A/A þ B ¼ 80.8%.
Predictive value of a negative test: D/D þ C ¼ 98.9%.
Table 3
Predictive powers of a test with 99% sensitivity and 99% specificity (5% prevalence).
Test result (99% sensitivity and 99% specificity) People truly with d
Positive 4950 (A)
Negative 50 (C)
Total 5000
Predictive value of a positive test: A/A þ B ¼ 83.8%.
Predictive value of a negative test: D/D þ C ¼ 99.9%.Table 1 shows that if the sensitivity is 90%, 4500 people will
correctly test positive, but 500 will incorrectly test negative and be
wrongly told they have no antibody evidence of the disease. If the
specificity is 90%, 85,500 people will correctly test negative, but
9500 will incorrectly test positive and be wrongly told they have
antibody evidence of previous infection. Thus, of the 14,000 people
who received positive test results, only 32% (4500/14,000; A/A þ B)
had the disease. This is referred to as the predictive value (or po-
wer) of a positive test. The other 68% would be given wrong in-
formation. Of the 86,000 people who received negative tests, 99%
(85,500/86,000; D/C þ D) would receive a correct result. This is
called the predictive value (or power) of a negative test.
Sensitivity and specificity vary with different tests but, for any
particular antibody test, these can be adjusted by altering the level
of antibody required to determine a positive result. Requiring a
higher level of antibody for a positive result would increase the
specificity but lower the sensitivity. This would reduce the false
positives (C) but increase the false negatives (B). Choosing a test
that has 80% sensitivity and 99% specificity, as shown in Table 2, 81%
of people who test positive have had the disease, an increase from
32%. Now, about one in five people who test positive will not have
had the disease. This shows that when the prevalence of the disease
is low, antibody testing, even with a specificity as high as 99%, still
produces many false positives so the predictive power of a positive
test is far from 100%.
If a test is extremely accurate, as is claimed for the Roche and
Abbott systems, say 99% sensitivity and specificity, the results are
shown in Table 3. Even now, the predictive power of a positive test
has only risen from 81% with a sensitivity of 90%, to 83.8%. If the
prevalence rises to 20% then the predictive power of a positive test
is 96.1% and of a negative test 99.7% (Supplementary File
Table A12).
If immunity certificates, or personal or societal decisions about
returning to normality, are based on these results, a significant
proportion will be incorrect. Where the disease has become highly
prevalent, for example, among health care and care home workers,isease People truly without disease Totals
9500 (B) 14,000
85,500 (D) 86,000
95,000 100,000
isease People truly without disease Totals
950 (B) 4950
94,050 (D) 95,050
95,000 100,000
isease People truly without disease Totals
950 (B) 5900
94,050 (D) 94,100
95,000 100,000
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ance could be placed on it. Even with a prevalence of 20% and 99%
sensitivity and specificity, the test itself does not give a guarantee at
the individual level, and personal and clinical judgements are
required in applying the findings. A major hope of antibody testing
is that thosewho test positive can resumework and social activities
more fully and confidently than those who test negative. The
presence of antibodies should signify the same illness will not
recur, the person is not contagious and there is at least partial
immunity to future COVID-19 infections. We need to establish
whether this is true.10
If the purpose of antibody testing is to assess the prevalence of
COVID-19 in a representative sample of the population, these
clinical issues do not apply. The veracity of the prevalence derived
by such measurements will depend upon achieving equal false
positives and false negatives. For example, although the true
prevalence is 5%, Tables 1e3 give a prevalence in the hypothetical
population of 100,000 people of 14% (14,000 positives), 4.95% (4950
positives), and 5.9% (5900 positives), respectively. Perhaps sur-
prisingly, the test with 80% sensitivity and 99% specificity (Table 2)
gives the most accurate estimate at this level of population
prevalence.
In conclusion, at currently reasonable estimates of the general
population prevalence, even high sensitivity and specificity will
produce an important number of false positives. People testing
positive, especially those without indicative case histories, may
need further testing to confirm the result. Given the current un-
certainty about the level of immunity signalled by antibodies, all
those testing positive for antibodies would be well advised to
maintain protective measures. More information is also urgently
needed to ascertain the strength and duration of immunity in
people who have recovered from COVID-19, and whether some can
still be infectious or become reinfected. Giving false security and
reassurance could be harmful for individuals, undermine public
confidence and foster further outbreaks.
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